31.03.2015 04:59:00

Catamaran Corporation -- Moody's puts Catamaran's ratings on review for upgrade following news of acquisition by OptumRx

New York, March 30, 2015 -- Moody's Investors Service placed Catamaran Corporation's ratings, including its Ba2 Corporate Family Rating, on review for upgrade. The action follows the announcement that OptumRx, UnitedHealth Group Incorporated's independent pharmacy benefit manager (PBM), plans to acquire Catamaran, which will involve UnitedHealth issuing up to $13 billion of new debt. In addition, UnitedHealth will assume the senior unsecured notes of Catamaran. Moody's affirmed UnitedHealth's A3 debt rating but changed the outlook to negative earlier today.

Vollständigen Artikel bei Moodys lesen